All Stories

  1. Precision Medicine in Acromegaly: The Potential of Multimodal Therapy
  2. No effect of surgery on kidney and cardiovascular risk factors in mild primary hyperparathyroidism: secondary analyses from a 10-year randomized controlled trial
  3. Acromegaly management in the Nordic countries: A Delphi consensus survey
  4. Unravelling pituitary tumours in medically treated patients with acromegaly: the impact of systematic MRI reassessment
  5. Long-term depot specific changes in adipose tissue after treatment of acromegaly
  6. Endocortical Trabecularization in Acromegaly: The Cause for the Paradoxically Increased Vertebral Fracture Risk?
  7. Endoskopisk firehåndsteknikk ved hypofysesvulster
  8. TGFBR3L is associated with gonadotropin production in non-functioning gonadotroph pituitary neuroendocrine tumours
  9. Gene expression profiling of subcutaneous adipose tissue reveals new biomarkers in acromegaly
  10. Trends in incidence and mortality risk for acromegaly in Norway: a cohort study
  11. Mortality and Morbidity in Mild Primary Hyperparathyroidism: Results From a 10-Year Prospective Randomized Controlled Trial of Parathyroidectomy Versus Observation
  12. Sex difference in patients with controlled acromegaly—A multicentre survey
  13. Current clinical practice for thromboprophylaxis management in patients with Cushing’s syndrome across reference centers of the European Reference Network on Rare Endocrine Conditions (Endo-ERN)
  14. European expert consensus on practical management of specific aspects of parathyroid disorders in adults and in pregnancy: recommendations of the ESE Educational Program of Parathyroid Disorders (PARAT 2021)
  15. The Influence of DXA Hardware, Software, Reference Population and Software Analysis Settings on the Bone Mineral Density and T-Score Relationship
  16. Silent, isolated ACTH deficiency in malignant melanoma patients treated with immune checkpoint inhibitors
  17. Effects of Parathyroidectomy on Quality of Life: 10 Years of Data From a Prospective Randomized Controlled Trial on Primary Hyperparathyroidism (the SIPH ‐Study)
  18. Hip Structure Analyses in Acromegaly: Decrease of Cortical Bone Thickness After Treatment: A Longitudinal Cohort Study
  19. MANAGEMENT OF ENDOCRINE DISEASE: Individualised management of acromegaly
  20. Parathyroid hormone independent hypercalcemia in adults
  21. The effect of surgery on fat mass, lipid and glucose metabolism in mild primary hyperparathyroidism
  22. Targeting either GH or IGF-I during somatostatin analogue treatment in patients with acromegaly: a randomized multicentre study
  23. Effect of Surgery Versus Observation: Skeletal 5-Year Outcomes in a Randomized Trial of Patients With Primary HPT (the SIPH Study)
  24. Treatment of acromegaly increases BMD but reduces trabecular bone score: a longitudinal study
  25. Insulin sensitivity, body composition and adipose depots following 12 w combined endurance and strength training in dysglycemic and normoglycemic sedentary men
  26. Treatment of acromegaly increases BMD but reduces Trabecular Bone Score - a longitudinal study
  27. MR-undersøkelse predikerer behandlingsrespons ved akromegali
  28. MRI T2 characteristics in somatotroph adenomas following somatostatin analog treatment in acromegaly
  29. Quantitative analyses of T2-weighted MRI as a potential marker for response to somatostatin analogs in newly diagnosed acromegaly
  30. Effects of Parathyroidectomy Versus Observation on the Development of Vertebral Fractures in Mild Primary Hyperparathyroidism
  31. The Metabolic Risk in Patients Newly Diagnosed with Acromegaly Is Related to Fat Distribution and Circulating Adipokines and Improves after Treatment
  32. Metabolic improvement after treatment of acromeglay is determined by the increase of gynoid fat mass and the decrease of serum vaspin and IGF1
  33. Expression of SSTR2a, but not of SSTRs 1, 3, or 5 in Somatotroph Adenomas Assessed by Monoclonal Antibodies Was Reduced by Octreotide and Correlated With the Acute and Long-Term Effects of Octreotide
  34. Epithelial Splicing Regulator Protein 1 and Alternative Splicing in Somatotroph Adenomas
  35. Attenuated RORC Expression in the Presence of EMT Progression in Somatotroph Adenomas following Treatment with Somatostatin Analogs Is Associated with Poor Clinical Recovery
  36. Differential effect of octreotide treatment on expression of sstr2a, 3 and 5 in somatotroph adenomas
  37. Intensity of pituitary adenoma on T2‐weighted magnetic resonance imaging predicts the response to octreotide treatment in newly diagnosed acromegaly
  38. Adenoma granulation pattern correlates with clinical variables and effect of somatostatin analogue treatment in a large series of patients with acromegaly
  39. Simple model for the effectiveness of PDT with pulsed-laser sources
  40. Photodynamische Therapie mit Photosan 3 und mikrosekunden Laserpulsen